Groundbreaking research at our labs and others has demonstrated that older animals, when transfused with the blood of young animals, experience regeneration across many tissues and organs. The opposite is also true: young animals, when transfused with the blood of older animals, experience accelerated aging. Elevian’s scientific founders identified specific circulating factors that may be responsible for these effects.
One example, a naturally occurring molecule known as “growth differentiation factor 11” (“GDF11”), when injected into aged mice, reproduces many of the regenerative effects of young blood. GDF11 supplementation reduces age-related cardiac hypertrophy, accelerates skeletal muscle repair, improves exercise capacity, improves brain function and cerebral blood flow, and improves metabolism. Our founder’s discoveries are published in leading journals and were recognized by Science as a global top 10 scientific breakthrough of 2014.
Elevian is developing a number of therapeutics that regulate GDF11 and other circulating factors, in order to restore our body’s natural regenerative capacity, which we believe address a root cause of age-associated diseases.
The following contains links to research from our team (in bold) and others, using websites owned and operated by third parties.
Conboy IM, Wagers AJ et al. Nature, 2005.
Loffredo FS,...,Wagers AJ, Lee RT. Cell, 2013.
Sinha M,...,Lee RT, Wagers AJ. Science, 2014.
Katsimpardi L,...,Lee RT, Wagers AJ, Rubin LL. Science, 2014.
Walker RG,...,Rubin LL, Wagers AJ, Lee RT. Circulation Research, 2016.
Walker RG,...,Wagers AJ, Lee RT et al. BMC Biology, 2017.
Walker RG,...,Lee RT et al. PNAS, 2018.
Ozek C,…, Rubin LL. Scientific Reports, 2018.
Olson KA et al. European Heart Journal, 2015.
Onodera K et al. Thorax, 2017.
Li et al. Diabetes, 2017.
Elliott BT et al. Physiological Reports, 2017.
Zhang et al. Journal of Alzheimer’s Disease, 2018.
Elevian Co-Founder; xPrize, Singularity U, Celularity, Human Longevity, Inc.
Elevian Co-Founder; Executive Director, Harvard Stem Cell Institute
Elevian Co-Founder; Head, Organ Manufacturing, United Therapeutics
Former Co-Founder & CSO, Stemcentrx & VP, Research and Development, AbbVie
Managing Partner, Life Science Advisory
Chief Medical Officer, Panorama Research Institute
about our mission
to patients, providers, society and our shareholders
to advance and grow
to never settle
to foster our best ideas
because we are stronger together
Professor Amy Wagers, Elevian Scientific Co-Founder
November 7, 2018
Dr. Mark Allen, Elevian Co-Founder & CEO
TEDx Palo Alto
April 29, 2018
Jan. 9, 2019 - In order to succeed in this endeavor, the companies will utilize state-of-the-art techniques in AI-enabled drug discovery.
Sept. 6, 2018 - Elevian, a new company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent age-related disease, launches at TechCrunch Disrupt's Startup Battlefield.
PRESS ABOUT US
Jan. 14, 2019 - The XTC 2019 Top 3 Finalists are ActiveProtective (Philadelphia, Pennsylvania), developing a wearable that protects the hips of older adults using wearable airbags, Elevian (Boston, Massachusetts), creating regenerative medicines, with the potential to treat and prevent many age-related diseases and Lynq (Brooklyn, New York), the the world’s most advanced long-range tracker.
Jan. 11, 2019 - The collaboration is aimed at developing oral medications targeting the GDF11, or growth differentiation factor 11, pathway and associated targets — a concept that Elevian has been working on since inception.
Jan. 9, 2019 - Insilico will apply its generative adversarial networks and reinforcement learning technologies to biological and structural target data from Elevian to identify small molecules that produce the intended biological actions.
Jan. 5, 2019 - Elevian develops regenerative medicines, with the potential to treat and prevent many age-related diseases and extend healthy lifespan, targeting a fundamental mechanism of aging: regenerative capacity, our body’s ability to heal itself, which declines with age.
Oct. 24, 2018 - While we’re still far away from these fountain of youth treatments on drugstore shelves, we may be seeing the first wave of what could ultimately redefine the human experience.
Sept. 10, 2018 - In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. The funding was from Bold Capital, led by Peter Diamandis, Elevian’s founding investor, WTI, Stanford StartX, Longevity Fund, Kizoo Ventures, Thynk Capital and others.
Sept. 10, 2018 - Regenerative medicine company Elevian Inc. (Allston, Mass.) launched on Sept. 6 with $5.5 million in seed funding from Bold Capital, WTI, Stanford StartX fund, Longevity Fund, Kizoo Ventures, Thynk Capital and additional undisclosed investors.
Sept. 10, 2018 - Startup Elevian has raised millions to investigate whether a specific protein in young blood can have rejuvenating effects, despite disagreements over whether the science behind the idea is sound.
Sept. 10, 2018 - Elevian is developing medicines that restore the body's regenerative capacity, with the potential to treat and prevent age-related diseases. Elevian’s founders, working at Stanford and Harvard, discovered that young blood stimulates regeneration of many tissues and organs in old animals.
Sept. 7, 2018 - A startup in San Francisco called Elevian has rounded up $5.5 million in seed cash to pursue its work on a regenerative medicine program.
Sept. 7, 2018 - It’s an amazing idea, and it could represent a feedback loop where for every year of life gained, new technological advances will add another year. It’s really neat to think about.
Sept. 7, 2018 - New startup Elevian has launched with $5.5 million in backing to develop drugs based on GDF11, a Harvard University-discovered protein that it says is linked to age-related diseases.
Sept. 6, 2018 - Today, the latest young-blood medicine-maker, Elevian, emerged from stealth with $5.5 million from investors including Peter Diamandis, one of the more prominent faces in the Silicon Valley “death disruption” scene. Beneath all the hype is some striking science.
Sept. 6, 2018 - A series of eye-catching papers on parabiosis experiments in mice, which identified a circulating protein that reverses aging-related tissue degeneration, has led to the formation of a new Harvard University spin-out, Elevian Inc., which has just closed a seed round of $5.5 million.
Sept. 6, 2018 - A company co-founded by former physician Mark Allen and several Harvard researchers are trying to develop a therapeutic to address aging to treat diseases like heart failure, coronary artery disease, and muscular dysfunction.
Sept. 5, 2018 - Age is the No. 1 risk factor behind most diseases in the developed world, according to numerous studies. That’s why Elevian, led by a team of Harvard researchers, is working to develop medicine that treats aging by restoring the body’s regenerative capacities.
Jul. 15, 2017 - Might that be true for people, too?
Dec. 18, 2014 - In work with profound implications for aging, researchers showed that blood from a young mouse can rejuvenate an old mouse's muscles and brain.
May 4, 2014 - After combining the blood circulations of two mice by conjoining them — one old, the other young — researchers found dramatic improvements in the older mouse’s muscle and brain. After four weeks, stem cells in both those areas got a boost of activity and were better able to produce neurons and muscle tissue.